Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $15

Vor Biopharma, Inc. +1.71%

Vor Biopharma, Inc.

VOR

15.43

+1.71%

Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ: VOR) with a Neutral and raises the price target from $9 to $15.